Skip to main content

Table 3 Hematological values in rats orally treated with HZJW

From: Gastroprotective and anti-Helicobacter pylori potential of herbal formula HZJW: safety and efficacy assessment

Parameter unit sex

Hematological values

0 mg/kg

1000 mg/kg

2500 mg/kg

5000 mg/kg

13 wk

26 wk

Recovery

13 wk

26 wk

Recovery

13 wk

26 wk

Recovery

13wk

26 wk

Recovery

RBC

1012/L

Male

9.18 ± 0.31

8.86 ± 0.47

8.65 ± 0.32

9.04 ± 0.33

8.72 ± 0.40

8.83 ± 0.45

9.27 ± 0.29

8.21 ± 0.71

8.48 ± 0.35

8.99 ± 0.80

8.94 ± 0.50

9.07 ± 0.71

Female

8.11 ± 0.28

7.90 ± 0.49

7.59 ± 0.55

8.30 ± 0.28

7.85 ± 0.69

8.01 ± 0.72

8.37 ± 0.79

7.84 ± 0.49

7.65 ± 0.41

8.58 ± 0.66

6.96 ± 1.47

7.90 ± 0.55

HGB

g/L

Male

174 ± 6

168 ± 6

170 ± 7

164 ± 7

166 ± 3

166 ± 3

171 ± 5

157 ± 11**

163 ± 5

168 ± 6

162 ± 6*

174 ± 8

Female

158 ± 2

162 ± 7

159 ± 10

163 ± 4

156 ± 12

167 ± 11

166 ± 10

155 ± 8

160 ± 10

166 ± 12

137 ± 29*

162 ± 4

HCT

%

Male

45.3 ± 1.3

43.7 ± 1.8

44.1 ± 1.8

43.9 ± 1.2

44.1 ± 1.1

43.3 ± 0.9

44.9 ± 1.3

42.2 ± 3.2

43.0 ± 1.4

44.4 ± 2.5

45.0 ± 2.4

46.5 ± 2.4

Female

40.8 ± 1.2

42.2 ± 2.3

40.7 ± 2.8

41.9 ± 1.2

41.6 ± 2.9

44.3 ± 3.1

42.2 ± 3.3

41.7 ± 2.4

41.0 ± 3.0

42.7 ± 2.6

37.8 ± 7.8

41.0 ± 1.7

MCV

fL

Male

49.3 ± 0.7

49.3 ± 1.2

51.0 ± 1.9

48.6 ± 1.7

50.6 ± 1.5

49.1 ± 1.6

48.4 ± 0.8

51.5 ± 1.8

50.7 ± 2.1

49.6 ± 3.3

50.3 ± 1.7

51.4 ± 1.5

Female

50.3 ± 1.4

53.5 ± 1.3

53.7 ± 2.4

50.5 ± 1.7

53.0 ± 1.7

55.4 ± 1.5

50.4 ± 0.9

53.2 ± 1.7

53.6 ± 1.3

49.8 ± 1.1

54.4 ± 1.6

52.0 ± 1.7

MCH

pg

Male

19.0 ± 0.2

19.0 ± 0.6

19.7 ± 0.8

18.1 ± 0.5

19.1 ± 0.7

18.8 ± 0.9

18.4 ± 0.3

19.1 ± 0.9

19.3 ± 0.7

18.8 ± 1.4

18.1 ± 0.7*

19.2 ± 0.7

Female

19.5 ± 0.7

20.6 ± 0.5

21.0 ± 0.8

19.7 ± 0.6

19.9 ± 0.7**

20.9 ± 0.8

19.9 ± 0.9

19.8 ± 0.6*

20.9 ± 0.5

19.4 ± 1.0

19.7 ± 0.9**

20.6 ± 0.9

MCHC

g/L

Male

385 ± 6

385 ± 7

386 ± 9

373 ± 9

376 ± 7*

383 ± 6

381 ± 4

371 ± 13*

380 ± 5

378 ± 10

361 ± 8*

374 ± 4*

Female

387 ± 8

385 ± 6

391 ± 8

389 ± 3

376 ± 7*

378 ± 8

395 ± 12

373 ± 6*

389 ± 8

389 ± 17

362 ± 16*

395 ± 7

RDW

%

Male

13.6 ± 0.5

13.3 ± 0.5

13.5 ± 0.4

13.7 ± 0.2

13.3 ± 0.3

13.4 ± 0.3

13.5 ± 0.3

13.3 ± 0.5

13.4 ± 0.5

13.7 ± 0.3

13.4 ± 0.4

13.4 ± 0.7

Female

13.1 ± 0.3

12.8 ± 0.3

12.6 ± 0.3

13.0 ± 0.3

12.7 ± 0.3

12.5 ± 0.2

12.9 ± 0.3

12.6 ± 0.3

12.9 ± 0.2

12.8 ± 0.3

13.0 ± 0.4

12.6 ± 0.5

PLT

109/L

Male

823 ± 87

906 ± 48

881 ± 107

797 ± 106

831 ± 71

906 ± 76

816 ± 39

819 ± 74

872 ± 42

795 ± 30

854 ± 69

940 ± 99

Female

763 ± 55

756 ± 98

828 ± 60

859 ± 122

816 ± 62

936 ± 72

810 ± 45

792 ± 94

839 ± 91

848 ± 86

696 ± 271

865 ± 76

MPV

fL

Male

3.3 ± 0.4

3.7 ± 0.5

4.2 ± 0.7

3.3 ± 0.4

3.7 ± 0.4

4.2 ± 0.4

3.4 ± 0.4

3.9 ± 0.5

4.2 ± 0.4

3.5 ± 0.4

4.7 ± 0.5**

4.5 ± 0.6

Female

3.4 ± 0.4

3.7 ± 0.5

4.1 ± 0.9

3.4 ± 0.4

4.0 ± 0.5

4.5 ± 0.2

3.5 ± 0.2

4.0 ± 0.6

4.4 ± 0.5

3.5 ± 0.4

4.6 ± 1.6

4.0 ± 0.2

PDW

%

Male

14.8 ± 0.5

14.4 ± 0.3

14.3 ± 0.6

15.3 ± 0.4

14.3 ± 0.6

13.9 ± 0.2

14.9 ± 0.5

14.3 ± 0.4

14.4 ± 0.5

15.2 ± 1.0

14.3 ± 0.4

14.6 ± 0.6

  

Female

15.0 ± 0.5

14.7 ± 0.3

14.4 ± 0.6

14.9 ± 0.4

14.7 ± 0.4

15.1 ± 0.8

15.3 ± 0.8

14.6 ± 0.6

14.5 ± 0.7

15.3 ± 0.6

15.2 ± 1.9

14.1 ± 0.2

PT

s

Male

14.4 ± 1.8

19.0 ± 5.8

15.1 ± 0.9

18.1 ± 3.9

17.1 ± 4.4

15.1 ± 0.4

13.5 ± 0.4

15.2 ± 3.2

14.7 ± 0.4

15.2 ± 2.6

15.7 ± 3.4

14.5 ± 0.6

Female

12.7 ± 0.6

13.4 ± 0.6

14.5 ± 0.5

12.4 ± 0.5

13.3 ± 0.5

14.4 ± 0.6

12.5 ± 0.3

13.7 ± 0.7

13.9 ± 0.5

12.5 ± 0.8

13.2 ± 1.0

14.1 ± 1.2

WBC

109/L

Male

6.4 ± 0.4

4.6 ± 1.1

4.7 ± 1.6

8.5 ± 3.4

6.6 ± 1.2**

5.2 ± 2.1

10.5 ± 2.7**

6.1 ± 2.3

5.2 ± 0.9

11.9 ± 2.2*

6.5 ± 2.2*

5.5 ± 1.2

Female

4.3 ± 1.2

3.1 ± 0.9

2.3 ± 0.6

6.0 ± 1.4

2.8 ± 0.8

2.4 ± 0.5

6.6 ± 2.5

3.1 ± 0.8

2.3 ± 0.6

6.9 ± 1.3

2.7 ± 1.2

2.7 ± 0.6

LYM

109/L

Male

5.0 ± 0.4

3.9 ± 0.9

4.1 ± 1.3

6.7 ± 3.1

5.3 ± 0.9**

4.4 ± 1.8

7.6 ± 1.8*

4.8 ± 1.8

4.3 ± 0.6

9.3 ± 2.1**

4.9 ± 1.6

4.4 ± 0.9

Female

3.5 ± 1.1

2.5 ± 0.7

1.9 ± 0.5

4.8 ± 0.8

2.2 ± 0.6

2.0 ± 0.4

5.3 ± 2.0

2.5 ± 0.6

1.9 ± 0.5

5.8 ± 1.4*

2.2 ± 1.0

2.2 ± 0.4

MON

109/L

Male

0.1 ± 0.0

0.0 ± 0.1

0.0 ± 0.0

0.2 ± 0.1

0.1 ± 0.0

0.0 ± 0.0

0.2 ± 0.2

0.1 ± 0.1

0.0 ± 0.0

0.3 ± 0.1

0.1 ± 0.1

0.1 ± 0.0

Female

0.1 ± 0.1

0.1 ± 0.2

0.0 ± 0.0

0.1 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

0.2 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

0.2 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

NE

109/L

Male

1.2 ± 0.3

0.6 ± 0.2

0.6 ± 0.3

1.6 ± 0.5

1.2 ± 0.3**

0.8 ± 0.3

2.6 ± 0.8**

1.2 ± 0.5**

0.9 ± 0.2

2.2 ± 0.4**

1.5 ± 0.7**

1.1 ± 0.3

Female

0.7 ± 0.3

0.5 ± 0.2

0.3 ± 0.1

1.0 ± 0.7

0.6 ± 0.2

0.4 ± 0.1

1.1 ± 0.7

0.6 ± 0.1

0.4 ± 0.1

0.9 ± 0.3

0.5 ± 0.2

0.5 ± 0.1

EOS

109/L

Male

0.0 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.1 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

Female

0.0 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

0.1 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.1

0.0 ± 0.0

0.0 ± 0.0

BAS

109/L

Male

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

Female

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

LYM

%

Male

77.7 ± 4.5

84.9 ± 0.9

86.7 ± 1.0

77.5 ± 5.2

80.7 ± 2.7**

83.4 ± 0.6**

72.8 ± 4.0

77.3 ± 2.4*

80.8 ± 1.8**

78.0 ± 4.7

75.9 ± 3.6**

79.0 ± 3.1**

Female

80.2 ± 6.1

80.0 ± 2.1

85.7 ± 0.7

80.3 ± 7.7

77.5 ± 3.7

83.9 ± 1.4*

79.8 ± 7.8

77.2 ± 2.3*

81.7 ± 2.6*

81.7 ± 6.2

78.9 ± 4.9

80.0 ± 2.0**

MON

%

Male

1.8 ± 0.3

1.1 ± 0.5

0.4 ± 0.1

1.9 ± 1.1

1.1 ± 0.4

0.5 ± 0.3

2.3 ± 0.7

1.4 ± 0.7

0.5 ± 0.2

2.7 ± 0.6

1.3 ± 0.5

1.1 ± 0.4

Female

1.5 ± 0.5

2.4 ± 4.3

0.3 ± 0.2

2.6 ± 0.5

0.9 ± 0.4

0.3 ± 0.3

2.7 ± 1.1

1.2 ± 0.6

0.6 ± 0.4

3.0 ± 0.6

0.9 ± 0.6

0.5 ± 0.3

NE

%

Male

19.5 ± 4.8

13.4 ± 0.7

12.3 ± 1.1

20.0 ± 4.8

17.6 ± 3.0**

15.8 ± 0.6

24.5 ± 4.0

20.6 ± 2.6*

18.1 ± 1.7

18.7 ± 4.3

22.0 ± 3.6**

19.3 ± 3.4

Female

16.8 ± 6.3

16.9 ± 4.4

13.8 ± 0.7

15.5 ± 7.9

20.7 ± 3.5

15.2 ± 1.5

16.6 ± 8.7

20.6 ± 2.7*

16.7 ± 2.6

14.2 ± 6.0

19.3 ± 4.1

18.7 ± 1.8

EOS

%

Male

0.7 ± 0.3

0.4 ± 0.3

0.4 ± 0.4 0

0.4 ± 0.3

0.3 ± 0.2

0.2 ± 0.1

0.3 ± 0.2

0.4 ± 0.3

0.4 ± 0.3

0.5 ± 0.2

0.5 ± 0.4

0.4 ± 0.2

Female

1.2 ± 0.2

0.5 ± 0.2

0.1 ± 0.1

1.0 ± 0.3

0.5 ± 0.2

0.5 ± 0.1

0.7 ± 0.5

0.7 ± 0.5

0.8 ± 0.6

0.8 ± 0.4

0.8 ± 0.5

0.5 ± 0.4

BAS

%

Male

0.3 ± 0.1

0.3 ± 0.2

0.2 ± 0.1

0.2 ± 0.2

0.3 ± 0.2

0.2 ± 0.1

0.1 ± 0.1

0.3 ± 0.2

0.1 ± 0.1

0.1 ± 0.1

0.3 ± 0.1

0.2 ± 0.0

Female

0.2 ± 0.2

0.3 ± 0.3

0.1 ± 0.1

0.5 ± 0.2

0.4 ± 0.3

0.1 ± 0.1

0.2 ± 0.3

0.2 ± 0.2

0.2 ± 0.3

0.3 ± 0.1

0.1 ± 0.2

0.2 ± 0.3

RET

‰

Male

11 ± 4

21 ± 5

10 ± 3

14 ± 6

18 ± 3

12 ± 2

16 ± 3*

18 ± 7

11 ± 4

14 ± 4

21 ± 5

11 ± 4

  

Female

18 ± 4

21 ± 4

10 ± 3

19 ± 5

22 ± 4

17 ± 2

18 ± 4

18 ± 6

11 ± 3

14 ± 4

28 ± 7

10 ± 4

  1. Note: Red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular HGB (MCH), mean corpuscular HGB concentration (MCHC), red cell distribution width (RDW), platelets (PLT), mean platelet volume (MPV), platelet distribution width (PDW), white blood cell (WBC) counts, reticulocytes (RET), neutrophils (NE), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), and basophils (BAS) prothrombin time (PT). Values are mean ± S.D. (n = 5 (4 weeks), 10 (26 weeks) or recovery (30 weeks)/sex/dose). * P < 0.05 & ** P < 0.01 compared with normal group.